Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
Toxicity from gabapentin, pregabalin, and other relatively ineffective drugs for chronic pain (all drugs licensed marketed for this purpose) could be reduced if prescribers better understood the real evidence. Despite the frequent reiteration that such drugs require prolonged titration and use to assess efficacy for an individual patient, this is not a scientific statement. When pain (or adverse effects such as sedation) have been assessed promptly, the onset of pharmacological effects is as rapid as one would expect from the short elimination half-lives for these drugs. (1) If people prescribe them, short prescriptions (e.g. 1 week) and prompt reassessment (within days) are "evidence-based". Adopting this practice might reduce prescriptions by a factor of 10 if not much more, by revealing how infrequently they have net benefit for anyone.